

Latest infection status,

○Trends in the number of new cases of infection

(Per 100,000 of the population)

	10/5~10/11		10/12~10/18		10/19~10/25	
Nationwide	4.40 (5,556)	↓	2.87 (3,616)	↓	1.64 (2,065)	↓
Hokkaido	2.44 (128)	↓	3.47 (182)	↑	1.45 (76)	↓
Saitama	4.37 (321)	↓	2.61 (192)	↓	1.16 (85)	↓
Chiba	4.36 (273)	↓	2.12 (133)	↓	1.10 (69)	↓
Tokyo	5.50 (765)	↓	2.89 (403)	↓	1.49 (207)	↓
Kanagawa	5.59 (514)	↓	3.01 (277)	↓	1.26 (116)	↓
Aichi	4.48 (338)	↓	2.86 (216)	↓	1.96 (148)	↓
Kyoto	5.96 (154)	↓	2.79 (72)	↓	2.05 (53)	↓
Osaka	11.28 (994)	↓	6.62 (583)	↓	4.08 (359)	↓
Hyogo	6.90 (377)	↓	3.77 (206)	↓	3.11 (170)	↓
Fukuoka	2.84 (145)	↓	2.35 (120)	↓	1.25 (64)	↓
Okinawa	10.25 (149)	↓	11.91 (173)	↑	7.43 (108)	↓

○Trends in the testing system

(Number of tests, positive rate)

	9/27~10/3		10/4~10/10		10/11~10/17	
Nationwide	367,884 ↓	2.7% ↓	388,022 ↑	1.5% ↓	338,281 ↓	1.1% ↓
Hokkaido	14,559 ↑	1.3% ↓	8,516 ↓	1.4% ↑	12,551 ↑	1.5% ↑
Saitama	26,971 ↑	2.4% ↓	27,111 ↑	1.3% ↓	21,021 ↓	0.9% ↓
Chiba	13,755 ↑	3.8% ↓	14,204 ↑	2.0% ↓	11,069 ↓	1.4% ↓
Tokyo	47,980 ↓	3.0% ↑	90,982 ↑	0.9% ↓	77,049 ↓	0.5% ↓
Kanagawa	19,248 ↑	4.1% ↓	22,824 ↑	2.3% ↓	18,072 ↓	1.7% ↓
Aichi	13,136 ↓	5.7% ↓	12,420 ↓	2.8% ↓	10,487 ↓	2.1% ↓
Kyoto	5,833 ↓	4.6% ↓	5,751 ↓	2.7% ↓	4,877 ↓	1.6% ↓
Osaka	53,661 ↑	3.1% ↓	54,605 ↑	1.9% ↓	49,334 ↓	1.2% ↓
Hyogo	14,718 ↑	4.5% ↓	15,730 ↑	2.5% ↓	8,017 ↓	2.6% ↑
Fukuoka	14,626 ↑	1.9% ↓	13,846 ↓	1.1% ↓	12,109 ↓	1.1% ↑
Okinawa	11,097 ↓	3.1% ↓	9,010 ↓	1.7% ↓	10,023 ↑	1.6% ↓

* ↑, ↓, and → indicate increase, decrease, and the same level, respectively, compared to the previous week.

Latest infection status, etc. (2)

○Trends in the number of inpatients

[Number of inpatients (Ratio to the no. of secured beds)]

○Trends in the number of severe patients


[Number of inpatients (Ratio to the no. of secured beds)]

	10/6	10/13	10/20	10/6	10/13	10/20
Nationwide	4,579 (11.5%) ↓	2,848 (7.2%) ↓	1,901 (4.8%) ↓	762 (13.8%) ↓	533 (9.7%) ↓	294 (5.3%) ↓
Hokkaido	106 (5.3%) ↓	49 (2.4%) ↓	57 (2.9%) ↑	3 (2.2%) ↓	0 (0.0%) ↓	1 (0.7%) ↑
Saitama	348 (19.6%) ↓	202 (11.4%) ↓	125 (7.0%) ↓	41 (22.4%) ↓	28 (15.3%) ↓	22 (12.0%) ↓
Chiba	231 (16.7%) ↓	157 (11.3%) ↓	107 (7.8%) ↓	44 (38.9%) ↓	26 (23.0%) ↓	7 (6.5%) ↓
Tokyo	733 (11.0%) ↓	465 (7.0%) ↓	266 (4.0%) ↓	262 (21.7%) ↓	179 (14.8%) ↓	93 (7.7%) ↓
Kanagawa	337 (16.9%) ↓	236 (11.8%) ↓	152 (7.6%) ↓	51 (24.3%) ↓	30 (14.3%) ↓	14 (6.7%) ↓
Aichi	239 (13.9%) ↓	123 (7.1%) ↓	78 (4.9%) ↓	23 (12.6%) ↓	12 (6.6%) ↓	5 (2.9%) ↓
Kyoto	87 (11.8%) ↓	62 (8.4%) ↓	27 (3.7%) ↓	14 (8.7%) ↓	11 (6.8%) ↓	2 (1.2%) ↓
Osaka	602 (17.6%) ↓	462 (13.5%) ↓	285 (8.3%) ↓	190 (14.7%) ↓	165 (12.7%) ↓	100 (7.7%) ↓
Hyogo	244 (18.0%) ↓	140 (10.3%) ↓	94 (6.9%) ↓	26 (18.3%) ↓	13 (9.2%) ↓	8 (5.6%) ↓
Fukuoka	178 (12.0%) ↓	99 (6.7%) ↓	60 (4.0%) ↓	20 (9.9%) ↓	16 (7.9%) ↓	9 (4.4%) ↓
Okinawa	99 (18.3%) ↓	42 (7.9%) ↓	40 (7.5%) ↓	17 (27.0%) ↓	4 (6.3%) ↓	6 (9.5%) ↑


* “Trends in the numbers of inpatients” are based on the “Surveillance of the Status of Care for Patients with the Novel Coronavirus Infection and the Number of Beds,” by the Ministry of Health, Labour and Welfare. With this surveillance, the results as of 0:00 on the presentation date are published.

↑, ↓, and → indicate an increase, a decrease, and the same level, respectively, compared to the previous week.


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment




(Source) ADB Material, dated October 26, 2021


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment




(Source) ADB Material, dated October 26, 2021


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients




(5) Use rate of beds




(6) No. of patients receiving treatment




(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment




(Source) ADB Material, dated October 26, 2021


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment




(Source) ADB Material, dated October 26, 2021


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment




(Source) ADB Material, dated October 26, 2021


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients









(5) Use rate of beds



(6) No. of patients receiving treatment




(Source) ADB Material, dated October 26, 2021




(Source) ADB Material, dated October 26, 2021


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment




(Source) ADB Material, dated October 26, 2021


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment




(Source) ADB Material, dated October 26, 2021


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds




(6) No. of patients receiving treatment




(Source) ADB Material, dated October 26, 2021


(1) No. of new cases of infection reported




(2) No. of new cases of infection (per 100,000 of the population)/Percentage of unlinked cases




(3) Test status




(4) No. of inpatients/No. of severe patients



(5) Use rate of beds



(6) No. of patients receiving treatment



(Source) ADB Material, dated October 26, 2021